Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 17Phase NA 5Phase 4 5Phase 2/3 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Hematologic Neoplasms 1Fatigue 1Critical Illness 1Anemia 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Darbepoetin alfa × Clear all
NCT00381836 2015-12-04

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

University of Aarhus

Phase 2/3 Terminated
140 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Neoplasms, Prostatic Neoplasms, Critical Illness

NCT00557817 2010-01-11

Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)

University of Liege

Phase 2/3 Completed
125 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡